# Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

> **NCT05327803** · PHASE2,PHASE3 · TERMINATED · sponsor: **AN2 Therapeutics, Inc** · enrollment: 177 (actual)

## Conditions studied

- MAC Lung Disease
- Treatment Refractory MAC Lung Disease

## Interventions

- **DRUG:** Epetraborole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05327803
- **Lead sponsor:** AN2 Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-20
- **Primary completion:** 2024-12-18
- **Final completion:** 2024-12-18
- **Target enrollment:** 177 (ACTUAL)
- **Why stopped:** EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study.
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05327803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05327803, "Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05327803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*